# A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

> **NCT02941601** · PHASE2 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Locally Advanced Squamous Non-Small Cell Lung Cancer
- Metastatic Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Necitumumab
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02941601
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-11
- **Primary completion:** 2017-12
- **Final completion:** 2019-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This was a strategic decision for business planning purposes and not out of concern for patient safety.
- **Last updated:** 2019-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02941601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02941601, "A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02941601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*